RIGVIR LTD

General Information
Registration number: 
40103763354
Year of foundation: 
2014
Industry (NACE 2): 
MANUFACTURING
21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1 Manufacture of basic pharmaceutical products
21.10 Manufacture of basic pharmaceutical products
PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
70 Activities of head offices; management consultancy activities
70.1 Activities of head offices
70.10 Activities of head offices
70.2 Management consultancy activities
70.21 Public relations and communication activities
70.22 Business and other management consultancy activities
Head of the company, position: 
Mr Jurģis Auziņš - Member of the Board
Number of employees: 
11 - 20
Turnover (EUR):
500 001 - 1 000 000
2016
500 001 - 1 000 000
2015
Export volume (EUR):
No data
2016
No data
2015
Export countries: 
Australia
Canada
United Kingdom
United States of America
Contact Information
Address: 
Kūdras iela 7 - 8, Olaine, Olaines novads, Latvija
E-mail: 
rigvir [at] rigvir [dot] com
Contact person, position: 
Mr Jurģis Auziņš - Member of the Board
Languages spoken : 
English
Latvian
Russian
Business Profile and Cooperation Interests
Business profile: 

RIGVIR® - the worlds first oncolytic virotherapy medicine, which is approved for cancer treatment and introduced in medical practice. RIGVIR® contains a live nonpathogenic ECHO-7 virus that has not been genetically modified.

RIGVIR® is oncotropic and oncolytic virus. It finds and selectively infects tumour cells. Then replicates in tumour cells and destroys them. Both of these processes, oncotropism and oncolysis, are selective for tumour cells and normal healthy cells are minimally if at all affected.

Oncolytic virotherapy with RIGVIR® is safe and effective cancer treatment, which improves time to progression, survival and quality of life of cancer patients.

Cooperation interests: 

See business profile.